Cargando…
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia. The prevalence of AD is expected to increase as the population ages, placing an additional burden on national healthcare systems. There is a large need for new di...
Autores principales: | Klyucherev, Timofey O., Olszewski, Pawel, Shalimova, Alena A., Chubarev, Vladimir N., Tarasov, Vadim V., Attwood, Misty M., Syvänen, Stina, Schiöth, Helgi B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027827/ https://www.ncbi.nlm.nih.gov/pubmed/35449079 http://dx.doi.org/10.1186/s40035-022-00296-z |
Ejemplares similares
-
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
por: Bondarev, Andrey D., et al.
Publicado: (2022) -
Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
por: Nazarova, Victoria A., et al.
Publicado: (2022) -
Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
por: Namiot, Eugenia D., et al.
Publicado: (2023) -
Stem Cells in Clinical Trials on Neurological Disorders: Trends in Stem Cells Origins, Indications, and Status of the Clinical Trials
por: Namiot, Eugenia D., et al.
Publicado: (2022) -
The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
por: Namiot, Eugenia D., et al.
Publicado: (2023)